LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

NVO

65.43

-3.4%↓

Search

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.79 -15.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.79

Max

2.07

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-320K

-49M

Pelnas, tenkantis vienai akcijai

-0.2

Darbuotojai

194

EBITDA

12M

-45M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+262.5% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

25M

451M

Ankstesnė atidarymo kaina

17.36

Ankstesnė uždarymo kaina

1.79

Naujienos nuotaikos

By Acuity

50%

50%

209 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-13 23:20; UTC

Uždarbis

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

2025-05-13 23:48; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

2025-05-13 23:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-13 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

2025-05-13 23:24; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-05-13 23:24; UTC

Rinkos pokalbiai
Uždarbis

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

2025-05-13 22:58; UTC

Uždarbis

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

2025-05-13 22:58; UTC

Uždarbis

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

2025-05-13 22:58; UTC

Uždarbis

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

2025-05-13 22:58; UTC

Uždarbis

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

2025-05-13 22:38; UTC

Uždarbis

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

2025-05-13 22:38; UTC

Uždarbis

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

2025-05-13 22:37; UTC

Uždarbis

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

2025-05-13 22:36; UTC

Uždarbis

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

2025-05-13 22:35; UTC

Uždarbis

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

2025-05-13 22:34; UTC

Uždarbis

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

2025-05-13 22:33; UTC

Uždarbis

Aristocrat: Interactive Business Delivered Strong Revenue Growth

2025-05-13 22:33; UTC

Uždarbis

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

2025-05-13 22:33; UTC

Uždarbis

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

2025-05-13 22:30; UTC

Uždarbis

Aristocrat Interim Dividend 44 Australian Cents/Share

2025-05-13 22:30; UTC

Uždarbis

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

2025-05-13 22:29; UTC

Uždarbis

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

2025-05-13 22:28; UTC

Uždarbis

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

2025-05-13 21:15; UTC

Uždarbis

Nu Holdings 1Q Rev $3.2B >NU

2025-05-13 21:03; UTC

Svarbiausios naujienos

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

2025-05-13 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-13 20:32; UTC

Uždarbis

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

2025-05-13 20:31; UTC

Uždarbis

Alcon 1Q Sales $2.45B >ALC.EB

2025-05-13 20:30; UTC

Uždarbis

Alcon 1Q Rev $2.47B >ALC.EB

2025-05-13 20:30; UTC

Uždarbis

Alcon 1Q EPS 70c >ALC.EB

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

262.5% į viršų

12 mėnesių prognozė

Vidutinis 7.25 USD  262.5%

Aukščiausias 11 USD

Žemiausias 5 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

209 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.